Jan 2 (Reuters) - Neumora Therapeutics (NMRA.O), opens new tab said on Thursday its experimental drug to treat depression failed to meet the main goal of a late-stage study. The study, first of the ...

In a highly anticipated readout for the kappa opioid receptor class in major depressive disorder, Neumora’s navacaprant ...

Neumora Therapeutics ( NMRA) shares crashed 80% to an all-time low Thursday when the biopharmaceutical firm announced that a ...

Neuroscience drug developer Neumora Therapeutics released highly anticipated results from the first of three Phase 3 trials ...

Vagus nerve stimulation therapy improved the symptoms of treatment-resistant depression for nearly 500 participants in a ...

The well-funded biotech lost most of its value after its drug flunked a late-stage trial. One analyst described the results ...

A drug that combines an atypical antipsychotic and an SSRI is under FDA review, and if approved will be the first ...

The clinical-stage biopharmaceutical company said the Phase 3 study didn't demonstrate a statistically significant improvement on the primary endpoint of change from baseline in a scale that measures ...

A thin wire connects the device to the left vagus nerve in the neck – a major nerve that serves as a communication highway ...

In a groundbreaking Interview, Professor Raz Yirmiya discusses his innovative research at the intersection of inflammation ...

Experts say chronic depression affects a lot of adults here in Oklahoma, and they say that the weather, seasonal depression, ...

A groundbreaking depression treatment co-pioneered by Queensland researchers using a new form of brain stimulation will begin ...